Combined use of biotine and thiamine for prevention and treatment of Hungtington Disease

CSIC and the CIBERNED have determined that the combined administration of biotin and thiamine is capable of improving motor symptoms and reducing striatal atrophy associated with Huntington Disease (HD).

Industrial partners from pharmaceutical industry are being sought to collaborate through a patent licence agreement.

An offer for Patent Licensing

Works on in vivo trials

There is no cure or prevention for Huntington Disease (HD), nor is there a known way to stop the worsening of the disease. The average life expectancy is approximately twenty years from the first clinical manifestation. Although HTT lowering strategies currently in clinical trials are promising therapeutic strategies, they are challenged by limitations associated to efficacy of delivery of the gene therapy to the basal ganglia and toxicity issues. It is therefore important to elucidate the molecular mechanisms by which the triggering mutation elicits its toxicity as a way to find easily druggable targets.

Through a detailed research of CPEB1 and CPEB4 protein expression the researchers have discovered a decrease in protein levels of the thiamine transporter (encoded by the SLC19A3 gene) in the striatum of subjects with HD, as well as the decrease in thiamine levels in the cerebrospinal fluid and in the brain of said subjects with HD. These results gave rise to think that a combination therapy with biotin and thiamine administration would be effective for HD patients, the goal of this treatment is to delay and reduce symptoms and help the persons suffering from the disease to fend for themselves for as long as possible.



NPC Brain by National Institutes of Health (NIH) with CC PDM1.0

Main innovations and advantages

- Efficacy of combined biotine and thiamine treatments is already proven for biotin-thiamine-responsive basal ganglia disease (BTBGD), and our results indicate that HD disease is in part a phenocopy of BTBGD due to a decrease in SLC19A3 protein levels.
- Safety of the combined treatment is also granted given its use for BTBGD patients.
- Easy administration and accessibility of the combined vitamin therapy to affected brain regions.

Patent Status

Patent application suitable for international extension

For more information, please contact:

Eva Gabaldón Sahuquillo

Deputy Vice-Presidency for Knowledge Transfer

Spanish National Research Council (CSIC)

Tel.: +34 91 568 15 50

E-mail: eva.gabaldon@orgc.csic.es
comercializacion@csic.es